Amgen Inc.

My name is Jason and I will be your conference facilitator today for Amgen's second quarter 2022 financial results conference call. All lines have been placed on mute to prevent any background noise. There will be a question and answer session at the conclusion of the speaker's prepared remarks. To ensure that everyone has a chance to participate, we will request that you limit yourself to asking one question during the Q&A session. To ask a question, please press star and then the number one on your telephone keypad. To withdraw your question, please press pound. I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.

Okay, Jason. Thank you. Good afternoon, everybody, and welcome to our Q2 call. Lots to cover today, so we'll go ahead and jump right in. Some of the key themes you'll hear about today include continued volume-driven growth, our strategy of seeking both internal and external innovation, the latter exemplified by our announcement this morning of acquiring Chemocentrics, And lastly, navigating through a difficult macro environment. We have posted the slides for your background. We'll use non-GAAP financial measures in our presentation today, and some of the statements will be forward-looking. Our SEC filings identify factors that could cause our actual results to differ materially. So with that, I would like to turn the call over to our Chairman and CEO, Bob Bradway. Bob?

Okay. Hello, everyone, and thank you for joining our call. Today we'll be discussing our second quarter performance, as well as our planned acquisition of Chemocentrics, which all of us here are very excited about. Starting with our operating results, we delivered strong volume-driven growth in the second quarter, with unit volumes increasing 10%. Our innovative products performed well globally. Repatha, Otesla, Prolia, and Avenity all delivered double-digit sales growth in the quarter. Alkyprolis, Enplate, and Blinsaito in our innovative hematology oncology portfolio all generated record quarterly sales. Our two newest products, Lumicrast and Tezspire, are both off to strong starts. Lumicrast is now being prescribed for patients with non-small cell lung cancer in 25 countries around the world. Tezspire has made a big impact in a short period of time for a broad population of patients with severe asthma in the U.S. With our planned acquisition of Chemocentrics, we'll be adding another newly launched innovative product to our portfolio, Tavneos, which is for ANCA-associated vasculitis, which is a serious and sometimes life-threatening autoimmune disease. Tavneos is a terrific medicine, the first innovation in this space in more than 10 years and very much needed given the harsh side effects of the older treatments and the seriousness of the disease. This product also fits right in Amgen's strategic sweet spot. Our decades of leadership in immunology and nephrology will enable us to add value to the TAVNEOS launch, reaching many more patients and much more quickly than would otherwise have been possible. You'll hear from Murdo in a moment, but let me just say that opportunities like this don't come along often. We're really looking forward to working with the highly skilled and committed team from ChemoCentrics to realize the full potential of this very innovative product. We think we can make a difference for patients and earn an attractive return for our shareholders from this investment. Dave will talk about the pipeline shortly. Our innovative and biosimilar molecules are proceeding well through the pipeline. Highlights of course include the really encouraging data for our cardiovascular molecule, Opaziran, which we expect to move into phase three testing. On the oncology side, data from our bites or bispecifics in several solid tumors are giving us growing confidence in the role these molecules can play in diseases where there are still really big unmet medical needs like small cell lung cancer and prostate cancer. Across the board, our biosimilars are advancing the plan, setting us up for the growth of that business from future launches. Let me now turn to the current drug pricing debate in Washington. By now, it won't surprise you to hear that we're disappointed by the proposed legislation. For some time, we've been advocating for reforms that respect innovation and provide improved access to it. The proposed bill does neither. The bill will impose price controls, and price controls will stymie innovation. At a time when our nation needs more innovation, the result of this bill will be less of it. Adding to the problem, the bill does precious little to improve the affordability of medicines for patients. So when it comes to innovation and affordability, this bill is lose-lose for patients. Recent developments are no surprise, however. We've been positioning our business for some time for a world of compressed life cycles and prices. And if adopted, this legislation would accelerate those trends, and we'll adapt accordingly. We continue to believe that the world needs more innovation, not less, and our focus will remain on advancing more of it. Across inflammation, oncology, and general medicine, we have a broad portfolio of innovative and biosimilar products meeting the needs of patients globally, and we remain encouraged by the prospects for our long-term growth. Through the first half of the year, our team performed well, meeting the needs of the patients we serve. I'm grateful to them for their dedication to our mission. And let me turn now over to Peter.